INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model

Item Type:	Article
Title:	INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model
Creators Name:	Graeser, R. and Esser, N. and Unger, H. and Fichtner, I. and Zhu, A. and Unger, C. and Kratz, F.
Abstract:	The (6-maleimidocaproyl)hydrazone derivative of doxorubicin (INNO-206) is an albumin-binding prodrug of doxorubicin with acid-sensitive properties that is being assessed clinically. The prodrug binds rapidly to circulating serum albumin and releases doxorubicin selectively at the tumor site. This novel mechanism may provide enhanced antitumor activity of doxorubicin while improving the overall toxicity profile. Preclinically, INNO-206 has shown superior activity over doxorubicin in a murine renal cell carcinoma model and in breast carcinoma xenograft models. In this work, we compared the antitumor activity of INNO-206 and doxorubicin at their respective maximum tolerated doses in three additional xenograft models (breast carcinoma 3366, ovarian carcinoma A2780, and small cell lung cancer H209) as well as in an orthotopic pancreas carcinoma model (AsPC-1). INNO-206 showed more potent antitumor efficacy than free doxorubicin in all tumor models and is thus a promising clinical candidate for treating a broad range of solid tumors.
Keywords:	Doxorubicin, (6-Maleimidocaproyl)Hydrazone Derivative of Doxorubicin, INNO-206, Prodrug, Human Serum Albumin, Tumor Models, Animals, Mice
Source:	Investigational New Drugs
ISSN:	0167-6997
Publisher:	Springer
Volume:	28
Number:	1
Page Range:	14-19
Date:	February 2010
Official Publication:	https://doi.org/10.1007/s10637-008-9208-2
PubMed:	View item in PubMed

Repository Staff Only: item control page